Bio-Rad launches IgA and IgM SARS-CoV-2

The Bio-Plex Pro Human IgA SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel and the Bio-Plex Pro Human IgM SARS-CoV-2 S1/S2/N/RBD 4-Plex Panel join Bio-Rad’s existing Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel to complete the set of three separate qualitative multiplex immunoassays that provide precise and efficient detection of IgA, IgG, and IgM antibodies against four SARS-CoV-2 antigens. The panels assist researchers in developing vaccines, and the panels also help public health researchers who perform seroprevalence studies based on serology specimens to identify individuals who may have been exposed to SARS-CoV-2. These individuals may have not been diagnosed with COVID-19 and could have experienced only mild symptoms, or they could be asymptomatic.

“The multiplex immunoassay panels help vaccine developers determine therapeutic efficacy, from development through clinical phases and then later on in postmarket surveillance studies” said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life Science Group. “Detecting levels of antibodies against SARS-CoV-2 in an individual provides valuable information about possible exposure rates in a population or about the effectiveness of COVID-19 vaccines in preventing the spread of this disease” she said.

Key Benefits

• Can be provided as a kit that includes all required reagents
• Help researchers simultaneously profile antibodies against four SARS-CoV-2 viral antigens: the nucleocapsid protein (N) and the receptor binding domain (RBD), and the spike 1 (S1) and spike 2 subunits (S2) of the spike protein
• Provide results in less than 3 hours
• Enable comparison of median fluorescence intensity (MFI) values of samples to help researchers and vaccine developers understand the strength of response and antibody levels at different time points after SARS-CoV-2 infection or vaccination

The Scientist